nggt002
Gene therapyexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 30, 2023 (NCT06061614)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Phenylalanine-4-hydroxylaseSupplementation
PAH supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06332807 | Phase 1/Phase 2 (Phase 2) | Nov 22, 2024 | Next Generation Gene Therapeutic |
| NCT06687733 | Phase 1/Phase 2 (Phase 2) | Jul 25, 2024 | Bengbu Medical College, Government of China |
| NCT06061614 | Early Phase 1 (Phase 1) | Mar 30, 2023 | Bengbu Medical College |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bengbu Medical College | Academic/Hospital | 2 | 1 | 2 | 2023 |
| Government of China | Government | 1 | 1 | 1 | 2024 |
| Next Generation Gene Therapeutic | For profit | 1 | 1 | 1 | 2024 |
3 organizations
Page 1 / 1